Bio-Techne (TECH) Competitors $52.53 +1.81 (+3.57%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TECH vs. A, MTD, WAT, ILMN, CRL, BIO, BRKR, PACB, HBIO, and TMOShould you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Charles River Laboratories International (CRL), Bio-Rad Laboratories (BIO), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), and Thermo Fisher Scientific (TMO). These companies are all part of the "life sciences tools & services" industry. Bio-Techne vs. Agilent Technologies Mettler-Toledo International Waters Illumina Charles River Laboratories International Bio-Rad Laboratories Bruker Pacific Biosciences of California Harvard Bioscience Thermo Fisher Scientific Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking. Which has better valuation & earnings, A or TECH? Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgilent Technologies$6.53B4.59$1.29B$4.3524.18Bio-Techne$1.20B6.94$168.10M$0.9953.06 Is A or TECH a better dividend stock? Agilent Technologies pays an annual dividend of $0.99 per share and has a dividend yield of 0.9%. Bio-Techne pays an annual dividend of $0.24 per share and has a dividend yield of 0.5%. Agilent Technologies pays out 22.8% of its earnings in the form of a dividend. Bio-Techne pays out 24.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio. Does the media prefer A or TECH? In the previous week, Bio-Techne had 2 more articles in the media than Agilent Technologies. MarketBeat recorded 31 mentions for Bio-Techne and 29 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 1.27 beat Bio-Techne's score of 1.14 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 22 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 17 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community favor A or TECH? Agilent Technologies received 467 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 71.04% of users gave Agilent Technologies an outperform vote while only 62.25% of users gave Bio-Techne an outperform vote. CompanyUnderperformOutperformAgilent TechnologiesOutperform Votes86671.04% Underperform Votes35328.96% Bio-TechneOutperform Votes39962.25% Underperform Votes24237.75% Is A or TECH more profitable? Agilent Technologies has a net margin of 19.27% compared to Bio-Techne's net margin of 13.22%. Agilent Technologies' return on equity of 25.56% beat Bio-Techne's return on equity.Company Net Margins Return on Equity Return on Assets Agilent Technologies19.27% 25.56% 13.47% Bio-Techne 13.22%12.73%9.75% Do insiders and institutionals believe in A or TECH? 87.4% of Agilent Technologies shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 0.3% of Agilent Technologies shares are owned by company insiders. Comparatively, 3.9% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend A or TECH? Agilent Technologies presently has a consensus target price of $146.25, suggesting a potential upside of 39.03%. Bio-Techne has a consensus target price of $81.25, suggesting a potential upside of 54.67%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than Agilent Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agilent Technologies 0 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.46Bio-Techne 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has more risk and volatility, A or TECH? Agilent Technologies has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. SummaryAgilent Technologies beats Bio-Techne on 13 of the 20 factors compared between the two stocks. Remove Ads Get Bio-Techne News Delivered to You Automatically Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECH vs. The Competition Export to ExcelMetricBio-TechneBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.30B$2.90B$5.35B$7.58BDividend Yield0.49%1.91%5.11%4.33%P/E Ratio53.0630.3721.6517.79Price / Sales6.94438.12376.3294.47Price / Cash28.30168.6838.1534.64Price / Book3.993.456.443.99Net Income$168.10M-$72.06M$3.20B$247.24M7 Day Performance0.42%4.36%6.67%5.84%1 Month Performance-15.49%-17.35%-6.27%-5.78%1 Year Performance-21.28%-31.05%8.56%-1.99% Bio-Techne Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECHBio-Techne4.9014 of 5 stars$52.53+3.6%$81.25+54.7%-21.3%$8.30B$1.20B53.063,000Positive NewsGap UpAAgilent Technologies4.6591 of 5 stars$103.48+0.5%$150.83+45.8%-25.3%$29.50B$6.51B23.7917,900Positive NewsGap UpMTDMettler-Toledo International4.0615 of 5 stars$1,033.42+1.1%$1,380.50+33.6%-14.1%$21.54B$3.87B25.5018,000Positive NewsGap UpHigh Trading VolumeWATWaters4.1418 of 5 stars$325.12+0.1%$401.31+23.4%+3.5%$19.32B$2.96B30.368,200Gap UpHigh Trading VolumeILMNIllumina4.598 of 5 stars$73.45-1.0%$140.65+91.5%-40.9%$11.63B$4.37B-9.569,030High Trading VolumeCRLCharles River Laboratories International4.7705 of 5 stars$133.97-2.1%$189.77+41.7%-55.9%$6.85B$4.05B893.1121,800Short Interest ↓Analyst RevisionGap UpHigh Trading VolumeBIOBio-Rad Laboratories4.6542 of 5 stars$229.42+1.7%$395.20+72.3%-16.7%$6.43B$2.57B-3.538,200Short Interest ↓Positive NewsGap UpBRKRBruker4.6192 of 5 stars$38.70+6.1%$68.00+75.7%-54.4%$5.87B$3.37B50.928,520Positive NewsGap DownHigh Trading VolumePACBPacific Biosciences of California2.6184 of 5 stars$1.32+7.3%$2.46+86.2%-58.4%$393.17M$154.01M-0.80730HBIOHarvard Bioscience3.672 of 5 stars$0.38-4.9%$4.50+1,082.7%-90.7%$16.77M$94.14M-1.15490Analyst ForecastGap UpTMOThermo Fisher Scientific4.9351 of 5 stars$437.800.0%$653.23+49.2%-20.6%$165.16B$42.88B26.49130,000Positive NewsGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies A Competitors MTD Competitors WAT Competitors ILMN Competitors CRL Competitors BIO Competitors BRKR Competitors PACB Competitors HBIO Competitors TMO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECH) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Techne Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Techne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
